Table 3.
HR | 95% CI | P-value | |
---|---|---|---|
Univariate Cox | |||
Age at outcome | 0.98 | 0.95–1.01 | 0.36 |
Gender | 0.83 | 0.36–1.91 | 0.66 |
Maximum LVWT at CMR1 | 1.10 | 1.03–1.17 | 0.007 |
LV mass at CMR1 | 1.01 | 0.99–1.01 | 0.12 |
LGE mass at CMR1 | 1.04 | 1.01–1.07 | 0.002 |
LGE Progression ≥4.75 g | 5.53 | 2.39–12.78 | <0.001 |
Interval between CMR1-CMR2 (days) | 1.00 | 0.99–1.00 | 0.39 |
LVEF CMR1 | 1.01 | 0.94–1.08 | 0.85 |
Apical vs. non-apical hypertrophy | 2.21 | 0.63–7.33 | 0.22 |
Genotypea | 1.94 | 0.66–5.69 | 0.23 |
Baseline SCD risk factors | 0.51 | 0.21–1.25 | 0.14 |
Multivariable Cox | |||
Age at outcome | 0.98 | 0.94–1.01 | 0.19 |
Maximum LVWT at CMR1 | 1.07 | 0.96–1.19 | 0.25 |
LGE mass at CMR1 | 0.98 | 0.94–1.03 | 0.52 |
LGE Progression ≥4.75 g | 5.04 | 1.85–13.79 | 0.002 |
CI, confidence interval; CMR, cardiac magnetic resonance imaging; HR, hazard ratio; LVEF, left ventricular ejection fraction; LVWT, left ventricular wall thickness; SCD, sudden cardiac death.
Sarcomeric and mitochondrial mutations vs. genotype negative.